Ethanamine,2-chloro-N,N-bis(2-chloroethyl)-, hydrochloride (1:1) cas no:817-09-4

NameEthanamine,2-chloro-N,N-bis(2-chloroethyl)-, hydrochloride (1:1)
CAS817-09-4
SynonymsEthanamine,2-chloro-N,N-bis(2-chloroethyl)-, hydrochloride (9CI); Triethylamine, 2,2',2''-trichloro-,hydrochloride (8CI); 2,2',2''-Trichlorotriethylamine hydrochloride;2-Chloro-N,N-bis(2-chloroethyl)ethanammonium chloride; NSC 30211; R 47;Sinalost; Tri(2-chloroethyl)amine hydrochloride; Tri(b-chloroethyl)amine hydrochloride;Trichlormethin; Trillekamin; Trimitan; Trimustine; Tris(2-chloroethyl)aminehydrochloride; Tris(b-chloroethyl)amine hydrochloride
EINECS(EC#)212-442-3
Molecular FormulaC6H12 Cl3 N . Cl H
Molecular Weight241.00

storage tempPoison room

Hazardclass6.1(a)

Hazard T+: Very toxic;Xi: Irritant;
Risk R26/27/28;R33;R40
Safety

Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects by ingestion and intravenous routes: somnolence, anorexia, headache, thrombosis distant from injection site, nausea or vomiting, and leukopenia. Experimental reproductive effects. Mutation data reported. Questionable carcinogen with experimental carcinogenic data. When heated to decomposition it emits very toxic fumes of Cl⁻, NH₃, and NO_x. Used as an antineoplastic agent.
Safety Information of Tris(2-chloroethyl)ammonium chloride (CAS NO.817-09-4):
Hazard Codes: T+,Xi
Risk Statements: 28-34-40
28:  Very Toxic if swallowed
34:  Causes burns
40:  Limited evidence of a carcinogenic effect
Safety Statements: 26-28-36/37/39-45
26:  In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
28:  After contact with skin, wash immediately with plenty of ... (to be specified by the manufacturer)
36:  Wear suitable protective clothing  
37:  Wear suitable gloves 
39:  Wear eye/face protection 
45:  In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) 

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD75	intravenous	1mg/kg (1mg/kg)	GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING	Journal of Pharmacology and Experimental Therapeutics. Vol. 90, Pg. 277, 1947.
human	TDLo	intravenous	100ug/kg (0.1mg/kg)	BEHAVIORAL: HEADACHE VASCULAR: THROMBOSIS DISTANT FROM INJECTION SITE GASTROINTESTINAL: NAUSEA OR VOMITING	National Technical Information Service. Vol. PB158-507,
human	TDLo	oral	30ug/kg (0.03mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ANOREXIA (HUMAN GASTROINTESTINAL: NAUSEA OR VOMITING	National Technical Information Service. Vol. PB158-507,
human	TDLo	oral	214ug/kg (0.214mg/kg)	BLOOD: LEUKOPENIA	National Technical Information Service. Vol. PB158-507,
mouse	LD50	intraperitoneal	1600ug/kg (1.6mg/kg)		Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 230, Pg. 559, 1957.
mouse	LD50	oral	1100ug/kg (1.1mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 9, Pg. 595, 1959.
mouse	LD50	subcutaneous	2mg/kg (2mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 224, 1947.
rabbit	LD50	intravenous	2500ug/kg (2.5mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 224, 1947.
rabbit	LDLo	oral	2mg/kg (2mg/kg)	GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS	British Journal of Pharmacology and Chemotherapy. Vol. 1, Pg. 247, 1946.
rat	LD50	intraperitoneal	750ug/kg (0.75mg/kg)		Chemical and Pharmaceutical Bulletin. Vol. 8, Pg. 807, 1960.
rat	LD50	intravenous	700ug/kg (0.7mg/kg)		National Technical Information Service. Vol. PB158-507,
rat	LD50	subcutaneous	2mg/kg (2mg/kg)		National Technical Information Service. Vol. PB158-507,
rat	LDLo	oral	5mg/kg (5mg/kg)		National Academy of Sciences, National Research Council, Chemical-Biological Coordination Center, Review. Vol. 5, Pg. 19, 1953.